Armata Pharmaceuticals, Inc. (ARMP)
| Market Cap | 81.41M |
| Revenue (ttm) | 4.70M |
| Net Income (ttm) | -426,000 |
| Shares Out | 36.18M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 745,756 |
| Open | 2.700 |
| Previous Close | 2.370 |
| Day's Range | 2.100 - 2.720 |
| 52-Week Range | 0.898 - 3.415 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+300.0%) |
| Earnings Date | May 14, 2025 |
About ARMP
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing syn... [Read more]
Financial Performance
In 2024, Armata Pharmaceuticals's revenue was $5.17 million, an increase of 14.24% compared to the previous year's $4.53 million. Losses were -$18.92 million, -72.60% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ARMP stock is "Strong Buy" and the 12-month stock price forecast is $9.0.
News
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best ...
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
LOS ANGELES , May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pur...
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia ...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
LOS ANGELES , March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-p...
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or...
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
LOS ANGELES , March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-p...
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -...
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
LOS ANGELES , Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacterio...
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
LOS ANGELES , Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacterioph...
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE Americ...
Armata Pharmaceuticals Announces Structural Biology Publication
Publication describes the structure of phage Pa193, a top candidate for inclusion into Armata's multi-phage anti-Pseudomonas clinical products LOS ANGELES , Oct. 30, 2024 /PRNewswire/ -- Armata Pharma...
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LOS ANGELES , Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-...
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
LOS ANGELES , Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-...
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-s...
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
LOS ANGELES , Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacterioph...
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia LOS ANGELES , July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE A...
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Tailwind is evaluating inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB), its second patient population, following successful evaluation in patients with cystic fibrosis (SWARM-P.a.) in 202...
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu...
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophag...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriop...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti...
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
LOS ANGELES , Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
LOS ANGELES , Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutic...